Comparative therapeutic efficacy and toxicity profile of low dose (35 mCi) versus high dose (70 mCi) 177Lu-EDTMP for bone pain palliation in metastatic prostate and breast cancer: Initial results from a randomized clinical trial

被引：0
|
作者：
Agarwal, Krishan K. [1 ]
Bal, Chandrasekhar [1 ]
Zaknun, John [2 ]
Sharma, Punit [1 ]
Naswa, Niraj [1 ]
Singla, Suhas [1 ]
Damle, Nishikant [1 ]
Malhotra, Arun [1 ]
机构：
[1] All India Inst Med Sci, New Delhi, India
[2] IAEA, Vienna, Austria
来源：
JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
223
引用
收藏
页数：1
相关论文
共 9 条
  • [1] Efficacy of 177Lu-EDTMP regarding improvement in mobility and bone pain palliation - Comparison of high dose therapy with low dose
    Akhtar, Ghazal
    Zaknun, John
    Saeed, Shabana
    Fatima, Shazia
    Butt, Sadaf
    Mariani, Giuliano
    Irfan, Javaid
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [2] Efficacy and toxicity profile of Lutetium-177-ethylenediamine tetramethylene phosphonate (EDTMP) for bone pain palliation in metastatic prostate and breast cancer: Initial results from clinical trial
    Agarwal, K. K.
    Bal, C.
    Singla, S.
    Sharma, P.
    Dhull, V. S.
    Khangembam, B. C.
    Zaknun, J.
    Malhotra, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S304 - S304
  • [3] Efficacy and toxicity profile of low dose 177 Lutetium-Ethylenediamine tetra methylene phosphonate (177Lu-EDTMP) for bone pain palliation in patients with skeletal metastases
    Halanaik, A. S. A. D.
    Pandit, N.
    Ponnusamy, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S371 - S372
  • [4] Efficacy and Safety of 177Lu-EDTMP in Bone Metastatic Pain Palliation in Breast Cancer and Hormone Refractory Prostate Cancer A Phase II Study
    Yuan, Jie
    Liu, Congjin
    Liu, Xingdang
    Wang, Yuankai
    Kuai, Dayu
    Zhang, Guangming
    Zaknun, John J.
    CLINICAL NUCLEAR MEDICINE, 2013, 38 (02) : 88 - 92
  • [5] Prostate high dose -rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy
    Morton, Gerard
    McGuffin, Merrylee
    Chung, Hans T.
    Tseng, Chia-Lin
    Helou, Joelle
    Ravi, Ananth
    Cheung, Patrick
    Szumacher, Ewa
    Liu, Stanley
    Chu, William
    Zhang, Liying
    Mamedov, Alexandre
    Loblaw, Andrew
    RADIOTHERAPY AND ONCOLOGY, 2020, 146 : 90 - 96
  • [6] Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy
    Morton, Gerard
    Chung, Hans T.
    McGuffin, Merrylee
    Helou, Joelle
    D'Alimonte, Laura
    Ravi, Ananth
    Cheung, Patrick
    Szumacher, Ewa
    Liu, Stanley
    Al-Hanaqta, Motasem
    Zhang, Liying
    Mamedov, Alexandre
    Loblaw, Andrew
    RADIOTHERAPY AND ONCOLOGY, 2017, 122 (01) : 87 - 92
  • [7] Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update
    Hudson, John M.
    Loblaw, Andrew
    Mcguffin, Merrylee
    Chung, Hans T.
    Tseng, Chia-Lin
    Helou, Joelle
    Cheung, Patrick
    Szumacher, Ewa
    Liu, Stanley
    Zhang, Liying
    Deabreu, Andrea
    Mamedov, Alexandre
    Morton, Gerard
    RADIOTHERAPY AND ONCOLOGY, 2024, 198
  • [8] Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial
    Yamamoto, Daigo
    Sato, Nobuaki
    Rai, Yoshiaki
    Yamamoto, Yutaka
    Saito, Mitsue
    Iwata, Hiroji
    Masuda, Norikazu
    Oura, Shoji
    Watanabe, Junichiro
    Hattori, Satoshi
    Matsuura, Yoshimasa
    Kuroi, Katsumasa
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (03) : 473 - 482
  • [9] Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial
    Daigo Yamamoto
    Nobuaki Sato
    Yoshiaki Rai
    Yutaka Yamamoto
    Mitsue Saito
    Hiroji Iwata
    Norikazu Masuda
    Shoji Oura
    Junichiro Watanabe
    Satoshi Hattori
    Yoshimasa Matsuura
    Katsumasa Kuroi
    Breast Cancer Research and Treatment, 2017, 161 : 473 - 482
1